Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Challenges with bringing novel immune therapies to MDS

Eric Padron • 9 Dec 2022
ASH 2022
Myelodysplastic Syndromes Checkpoint inhibitors

Eric Padron, MD, Moffitt Cancer Center, Tampa, FL, highlights challenges with bringing novel immune therapies to myelodysplastic syndromes (MDS). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eric Padron

CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for hematologists
Eric Padron et al. • 25 Mar 2024
1:31
The potential of bringing CAR-T therapy to MDS and challenges to overcome
Eric Padron • 9 Dec 2022
1:32
Phase II efficacy and safety results of ruxolitinib for patients with symptomatic CMML
Eric Padron • 9 Dec 2022
1:40
New therapeutic approaches targeting XPO1-overexpression in TP53-mutated myeloid malignancies
Eric Padron • 9 Dec 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024
1:21
HMAs for MDS- a party of one
Guillermo Garcia-Manero • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals